You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 92 No. 5, NOVEMBER 1953 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

GLUCAGON, THE HYPERGLYCEMIC AGENT IN PANCREATIC EXTRACTS

A Possible Factor in Certain Types of Diabetes

I. J. PINCUS, M.D., D.Sc.; J. Z. RUTMAN, B.S.

AMA Arch Intern Med. 1953;92(5):666-677.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

WITHIN the past 30 years tremendous strides have been made in our understanding of the pathways of intermediary metabolism and, more recently, in the study of the metabolic disturbances which may occur in disease. Despite the many studies which have been performed since the isolation of insulin, an understanding of the biochemical disturbances which occur in the diabetic patient is not forthcoming. The earlier concept, that this syndrome is produced by a simple insulin deficiency, has given way to the belief1 that in some instances various other factors may play a role. Among these may be glucagon, the hyperglycemicglycogenolytic factor.

Soon after Banting and Best2 extracted insulin from the pancreas, it became apparent that the crude preparations available contained an impurity which caused a rise in blood sugar level. Bürger and his co-workers3 and Collens, Murlin, and their associates4 studied this "contaminant," which they called glucagon. After Abel5 succeeded in . . . [Full Text PDF of this Article]


Author Affiliations

PHILADELPHIA

From the Department of Physiology and Division of Endocrine and Cancer Research, Jefferson Medical College, and Department of Gastroenterology, Graduate School of Medicine, University of Pennsylvania.


Footnotes

Supported in part by a research grant from Eli Lilly & Company, Indianapolis.

Read before the Section on Pathology and Physiology at the 102nd Annual Session of the American Medical Association, New York, June 3, 1953.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1953 American Medical Association. All Rights Reserved.